MATERIALS AND LINKS Meeting Information: Agenda Participant List Presentations: Opening Veronica Miller Kenneth Sherman Ira Jacobson Session 1 Gavin Cloherty Patrick Harrington Gabrielle Heilik Christoph Sarrazin Session 2 Tracy Swan Alain H. Litwin Session 3 HCV Drug Resistance Table Update

Background:
The Drug Development Advisory Group (DrAG) is an outgrowth of a proposal from the 1st International Workshop on Hepatitis C: Resistance and New Compounds in October 2006. The goal of HCV DrAG is to bring together parties interested in and working on various aspects of HCV drug/biologic drug development on a continuing basis to discuss issues pertinent in the field.

Objectives:  
The DrAG objectives are to produce consensus recommendations on a variety of issues in HCV drug/biologic development ranging from appropriate methodology for HCV resistance testing to providing scientific guidance by facilitating discussions among all stakeholders (industry, academia, patient advocates and regulatory agencies) on issues in HCV clinical trials.

 
Status:
The meeting was held on Thursday, November 3, 2011 at the San Francisco Marriott Marquis in San Francisco, CA.

The Steering Committee for this project includes:

Michelle Berrey, MD
Patrick Harrington, PhD
Ira Jacobson, MD
Filip Josephson, MD, PhD
**Dale Kempf, PhD
*Ann Kwong, PhD
Nina Mani, PhD, MPH
Veronica Miller, PhD
Isabel Najera, PhD
*Jean-Michel Pawlotsky, MD, PhD
Stuart Ray, MD
Kimberly Struble, PharmD
Tracy Swan

* Co-Chairs
** Past Co-Chair